Research programme: neurodegenerative disease therapeutics and diagnostics - Neuro-Bio

Drug Profile

Research programme: neurodegenerative disease therapeutics and diagnostics - Neuro-Bio

Alternative Names: NBP-14

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuro-Bio
  • Class Antidementias; Calcium regulators; Neuropeptides
  • Mechanism of Action Acetylcholinesterase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Neurodegenerative disorders

Most Recent Events

  • 04 May 2017 Early research in Neurodegenerative disorders in United Kingdom before May 2017 (unspecified route)
  • 22 Mar 2017 Neurodegenerative disease therapeutics and diagnostics - Neuro-Bio is available for licensing as of 01 May 2016. http://neuro-bio.com
  • 25 May 2016 Neuro-Bio intends to initiate phase I trials in 2017 (Neuro-Bio website, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top